13价肺炎球菌多糖结合疫苗 (辉瑞制药)(Pneumococcal polysaccharide conjugate vaccine) - 在研适应症：细菌性肺炎，急性中耳炎，侵袭性肺炎球菌病_专利_临床

概要

基本信息

药物类型

预防性疫苗、多价疫苗、结合疫苗

别名

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine、13vPnC、Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

+ [10]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染耳鼻咽喉疾病呼吸系统疾病+ [2]

在研适应症

细菌性肺炎急性中耳炎侵袭性肺炎球菌病+ [5]

非在研适应症

溃疡性结肠炎克罗恩病白喉+ [20]

原研机构

Pfizer Inc.

在研机构

Pfizer Europe MA EEIGWyeth Pharmaceuticals LLC

辉瑞投资有限公司

+ [5]

非在研机构

GSK PlcWyeth AB

赫力昂（苏州）制药有限公司

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (2009-10-16),

肺炎球菌感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

关联

182

项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的临床试验

TCTR20230923001

/ Not yet recruiting临床4期

Immunogenicity and Safety of Pneumococcal 13-valent Conjugate Vaccine between Weuphoria and Prevnar 13 in Thai Older People

开始日期2025-11-01

申办/合作机构-

CTRI/2025/02/081007

/ Not yet recruiting临床2/3期

A Randomized, Open label, Multicenter, Phase II / III study to assess and compare the immunogenicity and safety of NUCOVAC -11 {Pneumococcal Polysaccharide conjugate vaccine (Adsorbed), 11 valent} of Panacea Biotec Ltd. with PREVENAR 13 of Pfizer Inc. in healthy infants (3+1 immunization schedule) - Nil

开始日期2025-03-07

申办/合作机构

Panacea Biotec Ltd.

NCT06647407

/ Recruiting临床1/2期

A Parallel-group Prevention, Phase II, Partially Blinded, Multi-stage Study to Investigate the Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine Formulations Compared With Licensed Meningococcal Vaccines When Administered Alone in Healthy Children (2 to 9 Years of Age) or Concomitantly With Routine Pediatric Vaccines in Toddlers (12 to 15 Months of Age) and Infants (2 Months of Age).

This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age. The aim of the study is to assess 2 formulations of the MenPenta vaccine compared to licensed meningococcal vaccines when administered alone in children (Stage 1) or concomitantly with routine pediatric vaccines in toddlers (Stage 2) and infants (Stage 3).
Study details include:
The study duration per participant will be up to 12 months for children in Stage 1 and toddlers in Stage 2 and 16 to-19 months for infants in Stage 3.

开始日期2024-11-05

申办/合作机构

Sanofi Pasteur SA

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的临床结果

登录后查看更多信息

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的转化医学

登录后查看更多信息

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的专利（医药）

登录后查看更多信息

985

项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的文献（医药）

2025-08-01·Infectious Diseases Now

Impact of delaying PCV20 implementation in France’s pediatric national immunization program: A population-based Markov model

Article

作者: Fiévez, Stéphane ; Sabra, Ayman ; Beillat, Maud ; Blanc, Emmanuelle ; Perdrizet, Johnna ; El Khoury, Jessica Y ; Ilic, Aleksandar

OBJECTIVES:

We assessed the public health and economic impacts in France for infants below 1-year of delaying PCV20 (3 + 1) implementation compared to continuous use of PCV15 (2 + 1) and PCV13 (2 + 1).

PATIENTS AND METHODS:

Population-based Markov model was adapted for French pediatric population. Outcomes included pneumococcal disease cases, deaths, and direct costs. Impact of a PCV20 two-year implementation delay was reported by month, quarter, and year.

RESULTS:

Delaying PCV20 implementation in French children was estimated to result in preventable 15,356 disease cases and 1,489 deaths over two years, with cost of €117.4 million, versus the continuous use of PCV15. PCV20 versus PCV13 results were slightly reduced but followed a similar trend.

CONCLUSIONS:

Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources.

2025-07-01·Journal of Infection and Public Health

Cross-sectional investigation of pneumococcal vaccination patterns in HIV patients at a tertiary care hospital in Riyadh, Saudi Arabia

Article

作者: Alhubaishi, Alaa ; Mohzari, Yahya Ali ; Alsheheri, Ahmed Ajlan ; ALqutaym, Maram Saud ; Alderaan, Rowdan Zeyan ; Alrashed, Ahmed Ali ; Alnajjar, Lina I ; Otaif, Ethar Abdullhameed ; Alghamdi, Enas Mosaffer ; Binsuwaidan, Reem

BACKGROUND:

People living with HIV (PLWH) are recognized as a high-risk population for opportunistic infections, including community-acquired pneumonia (CAP). Therefore, the United States Centers for Disease Control and Prevention (US-CDC) and Saudi Ministry of health (MOH) advocate for pneumococcal vaccination among all PLWH as a crucial preventive measure against pneumococcal infections. Hence, this study aims to investigate the prescribing patterns of pneumococcal vaccines for PLWH at a tertiary care hospital. As PCV15 and PCV20 were not available until 2022, this study focuses on the prescribing patterns of PCV13 and PPSV23.

METHODS:

This cross-sectional study was conducted to assess the prescribing patterns of pneumococcal vaccines among PLWH attending the HIV clinic at a tertiary hospital in Riyadh, Saudi Arabia. Utilizing medical records from PLWH who visited the HIV clinic between January 1987 and December 2022, demographic data, clinical characteristics, antiretroviral therapy details, and pneumococcal vaccination records were collected. Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 21 (SPSS Inc., Armonk, New York, USA).

RESULTS:

Of the 346 identified patients, the majority (81 %) were male, with a median age of 45 years. A significant proportion had not received any pneumococcal vaccinations (98.6 %), while only 2 patients (0.56 %) completed the full series of pneumococcal vaccines (PCV13-PPSV23), and 3 patients (0.84 %) received a single dose of PCV13. Nearly all patients (99 %) reported regular attendance at the HIV clinic, with the vast majority (98.3 %) receiving antiretroviral therapy (ART).

CONCLUSION:

This study revealed a notable deficiency in pneumococcal vaccine coverage among PLWH. Therefore, additional measures are imperative to improve pneumococcal vaccine uptake and reduce the risk of invasive pneumococcal diseases within this vulnerable population.

2025-05-06·Microbiology Spectrum

Prevalence of pilus islets and association with clonal complex in Streptococcus pneumoniae isolated from children in Suzhou, China

Article

作者: Tao, Yunzhen ; Shen, Jiaming ; Wang, Mengzhen ; Huang, Lili ; Zhang, Tao ; Zhao, Genming ; Shao, Xuejun ; Zhang, Youyi ; Liu, Xiaofei

ABSTRACT:

Pilus islets (PIs) in Streptococcus pneumoniae play a crucial role in bacterial adhesion and virulence. This study aims to investigate the prevalence of PIs and explore their associations with serotypes, clones, and antibiotic susceptibility in S. pneumoniae isolated from children in Suzhou, China. A total of 341 S . pneumoniae isolates from aseptic specimens, ear secretions, and sputum between 2018 and 2021 were analyzed. Serotyping was conducted using latex and Quellung reactions. Antimicrobial susceptibility testing was performed using E-test methods. Multi-locus sequence typing (MLST) was conducted to identify the sequence types and clonal complex (CC). PI-1 and PI-2 were detected by PCR assays for the rlr A and sip A genes, respectively. A total of 63.6% of the included S. pneumoniae isolates expressed at least one type of PI, with strains of PCV13 vaccine serotypes showing a significantly higher positive rate of PIs than non-vaccine serotype strains (71.6% vs. 24.5%). PI prevalence varied across sample sources and clonal complexes. While a stronger association of PIs with clones than with serotypes was identified, most of the piliated isolates belonged to prevalent CCs, such as CC271. In addition, piliated isolates tended to be resistant to antibiotics compared to the non-piliated isolates. Our study highlights the high prevalence of PIs and the implications on antibiotic resistance and clonal dissemination of S. pneumoniae among children in Suzhou, China.

IMPORTANCE:

This study reveals a high prevalence of PIs in Streptococcus pneumoniae among children in China, which differs from isolates in other countries and highlights their implications for antibiotic resistance and clonal dissemination. To our knowledge, we are the first to report PI prevalence across different clinical samples within the same population, suggesting a potential link between PIs and acute otitis media (AOM) in Chinese children. These findings contribute valuable insights into the role of PIs in clinical settings and underline the need for targeted interventions, including vaccine strategies and antimicrobial stewardship protocols. By advancing our knowledge of PI epidemiology, this research enriches the existing literature and aims to inform public health initiatives, ultimately improving health outcomes for vulnerable pediatric populations.

173

项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的新闻（医药）

2025-05-21

·PRNewswire

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent of its vaccine, Prevnar 13. Continue Reading SK bioscience L HOUSE manufacturing plant However, the Supreme Court ruled that the individual conjugates comprising PCV13 do not fall within the scope of Pfizer's patent claims, thereby upholding the lower court's ruling in favor of SK bioscience. The Court also confirmed that the production and supply of PCV13 finished products for research purposes did not constitute patent infringement. SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire. Following the ruling, SK bioscience now plans to initiate new business in pneumococcal conjugate vaccines by exporting individual components of PCV13 to countries with high vaccine demand, such as those in Southeast Asia and Latin America. Technology transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine market. From 2027, the company will be able to manufacture and sell SKYPneumo domestically. In addition, the company is developing a 21-valent pneumococcal conjugate vaccine with global pharmaceutical company Sanofi, which entered Phase 3 global clinical in late 2024. Simultaneously, the two companies are also working on a next-generation pneumococcal vaccine that is expected to offer broader protection than current options. The global pneumococcal vaccine market continues to grow. According to Global Market Insights, the market is projected to grow at a compound annual rate of approximately 5.6% to reach USD 15.1 billion (approximately KRW 21.55 trillion) by 2034. This growth is driven by expanded vaccination programs and support from governments and international organizations like WHO and Gavi. SK bioscience's strong track record in public vaccine supply and cooperation with global health organizations positions it well for future expansion. Jaeyong Ahn, CEO of SK bioscience, said, "This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity. We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." Meanwhile, SK bioscience recently secured a definitive legal victory in a patent invalidation suit against Moderna, successfully challenging the biotech giant's Korean patent related to messenger RNA (mRNA) vaccine technology. The contested patent covers 'modified nucleosides, nucleotides, and nucleic acids and their uses.' This case, which invalidated the only registered mRNA manufacturing patent in Korea, regarded as a major step in reducing patent-related risks and removing barriers to innovation for domestic companies engaged in mRNA research and development. About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. - SK bioscience Website - SK bioscience Linkedin Contact SK bioscience Communications Team Changhyun Jin ([email protected]) Jeannie S. Pak ([email protected]) SOURCE SK bioscience WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗专利侵权信使RNA临床3期

2025-05-21

·Firstwordpharma

Pfizer loses pneumococcal vaccine patent case against SK bio

SK bioscience has emerged victorious in a long-running patent suit filed by Pfizer in 2020, with South Korea's Supreme Court ruling that the Korean company did not infringe on Pfizer's patent for its Prevnar 13 pneumococcal vaccine.The case centred on SK's export of individual conjugate bulk substances and research-use finished products for its own 13-valent pneumococcal conjugate vaccine (PCV13) to Russia. The court sided with SK, affirming an earlier lower court ruling that the specific components SK exported were outside the scope of Pfizer's patent. The Supreme Court also ruled that the production and supply of finished products for research purposes don't constitute infringement.Although SK remains barred from selling its own PCV13 vaccine — SKYPneumo, which it developed in 2016 — within South Korea until related Pfizer patents expire in 2027, the company says it now plans to export individual PCV13 components to markets with "high vaccine demand" such as those in Southeast Asia and Latin America, while at the same time pursuing technology transfer agreements with local partners.The company is simultaneously advancing a 21-valent pneumococcal conjugate vaccine with Sanofi, which entered Phase III testing last year, and developing next-generation pneumococcal vaccines offering broader protection.The victory follows another recent legal win against Moderna. In a patent invalidation case finalised last month, SK successfully nullified Moderna's Korean patent related to mRNA vaccine technology covering modified nucleosides, nucleotides and nucleic acids and their uses — reportedly the only such patent registered in the country. After nearly two years of review, the Korean Intellectual Property Trial and Appeal Board found the patent lacked legitimacy in terms of validity, priority and inventiveness. Moderna did not appeal the decision, which finalised the outcome in SK's favour.SK had argued that the patent was an unfair barrier to innovation, one that could have stifled the development of homegrown mRNA technologies. With that legal obstacle now out of the way, the company said last month that it was pushing ahead with its own mRNA vaccine pipeline, including GBP560, an mRNA-based Japanese encephalitis vaccine candidate in Phase I/II testing since February in Australia and New Zealand.

疫苗专利侵权信使RNA临床3期

2025-04-21

·CPHI制药在线

三战三败，辉瑞的烦恼不只GLP-1

关注并星标CPHI制药在线近日，辉瑞在口服GLP-1赛道再次失利，原因为潜在肝损伤风险，辉瑞因此决定终止该口服GLP-1受体激动剂（GLP-1R）danuglipron（PF-06882961）的临床开发。这已经是辉瑞在GLP-1赛道传来的第三次失败消息。更严峻的是，辉瑞的烦恼不止于此。三战三败，"安全性"是"罪魁祸首"辉瑞在GLP-1赛道的正式布局，始于2015年，通过与Sosei Heptares合作，辉瑞获得两款小分子GLP-1R激动剂：Lotiglipron（洛替格鲁肽）和Danuglipron（达努格鲁肽）。在后续研发中，进展并不顺利。2023年6月，辉瑞宣布将终止每日一次Lotiglipron的后续临床开发。这一决定基于I期药物相互作用研究的药代动力学数据，以及正在进行中的 I 期和 II 期研究中患者转氨酶升高的结果。消息发布后，辉瑞股价一度跳水超5%。2023年12月，辉瑞再次宣布将终止每日口服2次Danuglipron的临床研究。这一决定基于II 期临床数据所显示出的耐受性问题。研究结果显示，给药32周后，患者在各种剂量下均出现了显著的胃肠道不良反应，高达73%的患者出现了恶心，高达47%的患者出现呕吐，25%的患者出现腹泻。不良反应严重影响了患者的用药体验和依从性。在所有服药的患者中，有超过50%的患者选择停药，安慰剂组中这一比例约为40%。尽管Danuglipron（每日2次）的减重效果不错，在第26周和第32周的平均体重下降幅度分别为-5%~-9.5%和-8%~-13%，但由于严重的毒副作用，辉瑞决定放弃对每日2次Danuglipron的开发。为了减轻毒副作用，辉瑞在每日2次Danuglipron的基础上，开发了缓释剂型，即每日口服1次的Danuglipron。如今再次折戟。具体原因为，根据迄今为止入组的1400多例受试者数据，他们服用Danuglipron（每日1次）后发生肝酶升高的频率与其他GLP-1药物类似。不过，其中一项剂量优化研究中，1例无症状受试者发生了潜在的药物诱导性肝损伤，在停用Danuglipron后病情消退。最终在审查了全部信息后，辉瑞决定终止开发该分子。公告发布次日，辉瑞股价下跌2.3%，市值瞬间蒸发约29.5亿美元。"潜在肝损伤风险" 一直是小分子口服GLP-1药物开发的拦路虎。业内分析，小分子口服GLP-1药物由于需快速达到有效血药浓度，这或导致肝脏代谢压力骤增；而且相比大分子肽类药物，小分子还可能与非GLP-1受体发生交叉反应，因此增加肝毒性风险。经历三次失败后，辉瑞并未打算退出减肥领域。目前公司还剩下一款口服GIPR（葡萄糖依赖性促胰岛素多肽受体）拮抗剂PF-07976016，全球最高研发状态处于临床Ⅱ期。专利悬崖、临床失败，辉瑞进入瓶颈期当前辉瑞面临的最大威胁便是核心产品即将迎来专利悬崖：Eliquis、Prevnar（2026年）、Ibrance（2027年）、Xtandi（2027年）。抗凝药Eliquis（阿哌沙班）在2024年表现最为突出，销售额达到133亿美元，同比增长10%。但Eliquis核心专利将在2026年到期，届时面临仿制药争夺市场的困境。其次是肺炎球菌疫苗Prevnar family（Prevnar20和Prevnar13），2024年营收为64.11亿美元，但其专利将于2026年到期。另外乳腺癌领域首款获批的CDK4/6抑制剂Ibrance（哌柏西利）、前列腺癌领域王牌药物Xtandi（恩扎卢胺，雄激素受体抑制剂）也将于两年内失去市场独占权。面对重磅产品的专利悬崖，辉瑞通过并购进行产品迭代，试图找到新的重磅炸弹。比如以430亿美元收购Seagen，116 亿美元收购 Biohaven，67 亿美元收购阿里那制药、54亿美金收购GBT等。通过这些收购，虽然为辉瑞带来了收入增长，但也有在研产品进展不顺。通过收购Seagen获得的靶向B7-H4的 ADC药物Felmetatug vedotin，便因疗效不佳被辉瑞终止开发，"沉没成本"高达10亿美元。专利悬崖已近在咫尺，辉瑞正在急切寻找下一个增长极。对于减重这块大蛋糕，辉瑞并不想放弃，未来仍可能通过并购来汲取外部产品，重新争夺市场份额。如何在荆棘中再次摸索出一条大道，这考验着领导者的战略智慧。参考来源： 1. https://www.fiercebiotech.com/biotech/pfizer-axes-oral-glp-1-asset-over-liver-injury-blowing-hole-obesity-plan.2. https://endpts.com/in-a-blow-to-its-obesity-pipeline-pfizer-drops-danuglipron-after-liver-injury-case/.3. Analyst and Investor Call to Review Oral GLP-1 Data. Retrieved September 21, 2022, from https://s28.q4cdn.com/781576035/files/doc_presentation/2022/09/2022-EASD-IR_Presentation_FINAL.pdf.END【企业推荐】领取CPHI & PMEC China 2025展会门票智药研习社近期会议预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床结果临床2期临床失败

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	13价肺炎球菌多糖结合疫苗 (辉瑞制药)	J07AL02	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌性肺炎	日本	Pfizer Inc.	2013-06-18
中耳炎	美国	Wyeth Pharmaceuticals LLC	2010-02-24
急性中耳炎	欧盟	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	冰岛	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	挪威	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	欧盟	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	冰岛	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	挪威	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	欧盟	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	冰岛	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	挪威	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌感染	日本	Wyeth KK	2009-10-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
菌血症	临床3期	中国	John Wyeth & Brother Ltd.	2018-06-23
菌血症	临床3期	中国	Pfizer Ltd.	2018-06-23
菌血症	临床3期	中国	Wyeth Pharmaceuticals LLC	2018-06-23
菌血症	临床3期	中国	辉瑞投资有限公司	2018-06-23
脑膜炎	临床3期	中国	John Wyeth & Brother Ltd.	2018-06-23
脑膜炎	临床3期	中国	Wyeth Pharmaceuticals LLC	2018-06-23
脑膜炎	临床3期	中国	辉瑞投资有限公司	2018-06-23
脑膜炎	临床3期	中国	Pfizer Ltd.	2018-06-23
带状疱疹	临床3期	美国	GSK Plc	2018-04-12
带状疱疹	临床3期	加拿大	GSK Plc	2018-04-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04080531 (CTgov)	临床4期	浆细胞肿瘤 \| 多发性骨髓瘤 \| 流感病毒感染	165	Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Trivalent Influenza Vaccine, Prevnar))	襯襯網選製鏇繭蓋簾衊 = 鏇範獵憲衊膚網選窪夢製膚窪壓鹹鹹衊願積簾 (獵衊齋製觸製蓋襯鹽餘, 憲艱膚簾獵齋選製遞廠 ~ 壓願壓積鬱糧襯糧襯壓) 更多	-	2025-02-28
				Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Trivalent Influenza Vaccine, Prevnar))	襯襯網選製鏇繭蓋簾衊 = 夢衊繭衊獵鏇鹹膚願夢製膚窪壓鹹鹹衊願積簾 (獵衊齋製觸製蓋襯鹽餘, 願鹹獵顧糧蓋製糧鹽遞 ~ 餘艱網願製壓獵鹽遞糧) 更多
NCT04535037 (CTgov)	临床4期	白喉	500	DTPa-HBV-IPV/Hib+Pneumococcal 13-valent conjugate vaccine (Infanrix Hexa)	獵衊蓋選蓋構鹽壓廠構(鑰觸壓願蓋蓋夢遞鏇餘) = 糧簾選製鹽壓蓋醖醖餘遞鑰製壓製選願築鹽壓 (淵鏇膚艱廠鑰膚鑰遞窪, 鹽簾窪鬱築壓簾選醖簾 ~ 窪壓膚壓糧簾壓築膚範) 更多	-	2024-03-27
				Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis)	獵衊蓋選蓋構鹽壓廠構(鑰觸壓願蓋蓋夢遞鏇餘) = 衊淵製構鬱觸廠觸壓蓋遞鑰製壓製選願築鹽壓 (淵鏇膚艱廠鑰膚鑰遞窪, 鏇獵壓糧繭獵鑰遞鬱壓 ~ 積築鹽觸醖觸鹹醖衊簾) 更多
NCT05372575 (CTgov)	N/A	肺炎	300	13-valent pneumococcal conjugate vaccine (13vPnC)+13vPnC (13vPnC Cohort)	構夢築簾鏇鑰顧觸蓋廠(獵製鬱齋範願襯鑰遞簾) = 淵願壓憲蓋製廠觸鏇構糧艱蓋簾構艱膚膚餘積 (願範鹽簾構網壓艱糧艱, 積觸積鬱鏇繭鬱製鏇鏇 ~ 願遞選壓製窪網齋選顧) 更多	-	2023-10-03
				13vPnC (Non-13vPnC Cohort)	構夢築簾鏇鑰顧觸蓋廠(獵製鬱齋範願襯鑰遞簾) = 窪壓鑰衊鏇鹽網齋醖鑰糧艱蓋簾構艱膚膚餘積 (願範鹽簾構網壓艱糧艱, 網壓鹽夢顧鏇衊夢淵淵 ~ 繭網糧繭襯構壓齋壓鏇) 更多
NCT02274415 (DREVAC, Pubmed)	临床2期	镰状细胞血症	128	13-valent pneumococcal vaccinePPSV23eumococcal vaccine (PCV13/PPSV23)	鏇觸網淵艱繭艱積網鏇(壓膚簾積壓鹹鏇觸遞齋) = 觸構顧艱糧淵築願觸繭顧糧顧鬱廠襯鬱憲醖膚 (膚顧壓顧廠夢壓選網醖 ) 更多	积极	2023-01-27
				PPSV2313-valent pneumococcal vaccine (PPSV23 alone)	鏇觸網淵艱繭艱積網鏇(壓膚簾積壓鹹鏇觸遞齋) = 網築繭築繭憲蓋構糧膚顧糧顧鬱廠襯鬱憲醖膚 (膚顧壓顧廠夢壓選網醖 ) 更多
NCT03439657 (Pubmed \| J Infect)	临床3期	-	913	Adjuvanted Recombinant Zoster Vaccine	積窪繭糧築選壓膚衊築(鏇製積齋遞鹹繭鹹鬱壓): P-Value = 1.02 更多	积极	2021-12-25
				13-valent Pneumococcal Conjugate Vaccine
NCT03550313 (CTgov)	临床2期	肺炎球菌感染	565	c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration)	鹹願夢醖鏇衊齋選鹽觸 = 築願膚鬱範壓蓋餘壓願齋餘範壓餘鑰網遞衊淵 (餘鑰築醖膚築壓簾窪廠, 襯壓蓋獵顧壓網鹹鏇願 ~ 製鹽顧蓋觸襯膚蓋簾醖) 更多	-	2021-11-30
				c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration)	鹹願夢醖鏇衊齋選鹽觸 = 鑰鹹簾鹹遞觸窪網願願齋餘範壓餘鑰網遞衊淵 (餘鑰築醖膚築壓簾窪廠, 艱夢餘積鏇憲蓋遞憲鹹 ~ 糧糧鏇廠鬱顧廠網衊餘) 更多
NCT03439657 (CTgov)	临床3期	带状疱疹	913	HZ/su vaccine GSK1437173A+Prevenar13 (Co-Ad Group)	齋繭獵積獵築憲膚觸觸 = 積積願齋齋觸願醖鏇淵蓋繭蓋衊鬱簾鹽製顧範 (繭醖顧獵夢積網選簾遞, 膚簾廠鏇築襯窪簾齋廠 ~ 壓憲醖鏇鏇齋憲襯齋衊) 更多	-	2021-03-18
				HZ/su vaccine GSK1437173A+Prevenar13 (Control Group)	醖構鏇鏇鑰構鏇鏇鬱醖(製鹽製網簾築簾繭壓網) = 鏇觸範憲齋壓艱衊蓋醖糧鹽蓋壓簾鹽構窪網鏇 (膚衊餘顧鏇積遞觸窪遞, 廠築衊鹹鹹窪獵膚壓遞 ~ 夢襯選衊淵衊糧膚鏇襯) 更多
NCT02309515 (CTgov)	临床2期	甘露糖结合蛋白缺乏症 \| 淋巴细胞增多症 \| 慢性淋巴细胞白血病 ... 更多	12	Laboratory Biomarker Analysis+Lenalidomide+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine))	淵窪淵鹹願積夢觸廠衊 = 夢夢願遞糧壓膚餘夢壓網衊鬱糧鑰壓製艱顧廠 (鬱餘襯繭齋壓簾鹹範夢, 製鹹蓋鑰鹽糧選衊獵獵 ~ 膚顧繭願願觸醖觸蓋範) 更多	-	2021-01-19
				Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine))	淵窪淵鹹願積夢觸廠衊 = 築蓋壓鹹壓壓膚醖顧積網衊鬱糧鑰壓製艱顧廠 (鬱餘襯繭齋壓簾鹹範夢, 鹽製淵觸壓觸憲夢鏇憲 ~ 觸壓鹽窪衊築鹹夢夢鏇) 更多
NCT03548337 (CTgov)	临床4期	-	301	MDV+rotavirus vaccine+13vPnC (13vPnC: Multi-dose Vial (With Preservative))	鬱願鹹鹹餘艱獵繭築憲 = 醖獵齋廠艱夢網壓衊襯衊憲獵遞糧蓋淵夢衊糧 (範鹹蓋夢膚衊繭艱壓膚, 範製憲觸醖構糧製築築 ~ 齋範積夢膚醖鬱膚積蓋) 更多	-	2020-09-30
				DTP-Hib-HBV vaccine+rotavirus vaccine+13vPnC (13vPnC: Single-dose Prefilled Syringe (Without Preservative))	鬱願鹹鹹餘艱獵繭築憲 = 夢製齋窪簾獵壓築獵襯衊憲獵遞糧蓋淵夢衊糧 (範鹹蓋夢膚衊繭艱壓膚, 壓憲夢願蓋餘鏇觸遞遞 ~ 築繭衊遞夢襯遞鑰選鏇) 更多
NCT03313050 (CTgov)	临床2期	肺炎球菌感染	511	c7vPnC (Stage 1: c7vPnC (50 to 64 Years of Age))	醖網淵醖齋遞範蓋遞糧 = 鑰鹹範鏇襯艱製鬱蓋積廠膚夢觸鑰鏇製構鏇鹽 (廠構觸夢鏇繭壓餘蓋築, 鹽鹹範憲範淵壓築願糧 ~ 繭顧淵醖蓋鹹鹹壓淵獵) 更多	-	2020-06-04
				tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (Stage 1: Tdap (50 to 64 Years of Age))	醖網淵醖齋遞範蓋遞糧 = 顧壓簾願網製選願餘夢廠膚夢觸鑰鏇製構鏇鹽 (廠構觸夢鏇繭壓餘蓋築, 廠築膚簾廠網憲衊廠醖 ~ 觸淵鹽鬱構鑰鏇艱齋繭) 更多